Novartis readies first smart pill app

After investing $24 million earlier this year to gain access to cutting-edge smart pill technology, Novartis ($NVS) says it is 18 months away from filing for approval of its first chip-in-a-pill offering. The chips broadcast information to a skin patch, which in turn relays the information via smart phone. The first application will center on proper dosing for an approved drug that is used to prevent organ rejection among transplant patients. And because it is an existing drug, Novartis says that it only needs to prove bioequivalency rather than sponsor new clinical trials. Story

Suggested Articles

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.

After its mega $424 million IPO this summer, blood cancer focused Legend Biotech is making a big change at the top.

Kymera Therapeutics has a great year, nabbing a $102 million round for its march to the clinic, and now wants a $100 million IPO.